Home » Stocks » AlloVir

AlloVir, Inc. (ALVR)

Stock Price: $27.04 USD -1.06 (-3.77%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.66B
Revenue (ttm) n/a
Net Income (ttm) -28.80M
Shares Out 61.35M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $27.04
Previous Close $28.10
Change ($) -1.06
Change (%) -3.77%
Day's Open 28.28
Day's Range 26.76 - 28.96
Day's Volume 111,561
52-Week Range 18.15 - 45.28

More Stats

Market Cap 1.66B
Enterprise Value 1.56B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 61.35M
Float 27.07M
EPS (basic) n/a
EPS (diluted) -0.47
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.68M
Short Ratio 3.25
Short % of Float 6.21%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 17.85
Revenue n/a
Operating Income n/a
Net Income -28.80M
Free Cash Flow n/a
Net Cash 94.21M
Net Cash / Share 1.54
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(77.51% upside)
Current: $27.04
Target: 48.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-85.46%-
Gross Profit0.171.14
Operating Income-26.70-3.60
Net Income-23.84-2.43
Shares Outstanding1.920.30
Earnings Per Share-12.44-25.07
Operating Cash Flow-20.161.94
Capital Expenditures-0.34-
Free Cash Flow-20.491.94
Cash & Equivalents12624.96
Total Debt11.76-
Net Cash / Debt11424.96
Book Value-51.50-30.62
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AlloVir, Inc.
Country United States
Employees 21
CEO David L. Hallal

Stock Information

Ticker Symbol ALVR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALVR
IPO Date July 30, 2020


Allovir, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.